{"pmid":32333966,"title":"COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications.","text":["COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications.","Diabetes Res Clin Pract","Barchetta, Ilaria","Gisella Cavallo, Maria","Giorgio Baroni, Marco","32333966"],"journal":"Diabetes Res Clin Pract","authors":["Barchetta, Ilaria","Gisella Cavallo, Maria","Giorgio Baroni, Marco"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333966","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.diabres.2020.108165","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1665071049720463360,"score":8.518259,"similar":[{"pmid":32224164,"title":"COVID-19 and diabetes: Can DPP4 inhibition play a role?","text":["COVID-19 and diabetes: Can DPP4 inhibition play a role?","Diabetes Res Clin Pract","Iacobellis, Gianluca","32224164"],"journal":"Diabetes Res Clin Pract","authors":["Iacobellis, Gianluca"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32224164","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.diabres.2020.108125","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1664640912798515201,"score":81.63147},{"pmid":32333972,"title":"Letter to the Editor in response to the article \"COVID-19 and diabetes: Can DPP4 inhibition play a role?\"","text":["Letter to the Editor in response to the article \"COVID-19 and diabetes: Can DPP4 inhibition play a role?\"","Diabetes Res Clin Pract","Kokic Males, Visnja","32333972"],"journal":"Diabetes Res Clin Pract","authors":["Kokic Males, Visnja"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333972","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.diabres.2020.108163","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1665071049744580609,"score":72.15591},{"pmid":32333969,"title":"Response to COVID -19 and Diabetes: Can DPP4 Inhibition Play a Role? - GLP-1 Might Play One Too.","text":["Response to COVID -19 and Diabetes: Can DPP4 Inhibition Play a Role? - GLP-1 Might Play One Too.","Diabetes Res Clin Pract","Morin, Nathaniel","32333969"],"journal":"Diabetes Res Clin Pract","authors":["Morin, Nathaniel"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333969","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.diabres.2020.108160","keywords":["covid","glucagon like peptide 1 (glp-1)","hyperglycemia","interleukin 6 (il-6)"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1665071049731997696,"score":67.13826},{"pmid":32294179,"title":"Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications.","text":["Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications.","Individuals with diabetes are at increased risk for bacterial, mycotic, parasitic and viral infections. The severe acute respiratory syndrome (SARS)-CoV2 (also referred to as COVID-19) coronavirus pandemic highlights the importance of understanding shared disease pathophysiology potentially informing therapeutic choices in individuals with Type 2 diabetes (T2D). Two coronavirus receptor proteins, Angiotensin Converting Enzyme 2 (ACE2) and Dipeptidyl Peptidase-4 (DPP4) are also established transducers of metabolic signals and pathways regulating inflammation, renal and cardiovascular physiology, and glucose homeostasis. Moreover, glucose-lowering agents such as the DPP4 inhibitors, widely used in subjects with T2D, are known to modify the biological activities of multiple immunomodulatory substrates. Here we review the basic and clinical science spanning the intersections of diabetes, coronavirus infections, ACE2, and DPP4 biology, highlighting clinical relevance and evolving areas of uncertainty underlying the pathophysiology and treatment of T2D in the context of coronavirus infection.","Endocr Rev","Drucker, Daniel J","32294179"],"abstract":["Individuals with diabetes are at increased risk for bacterial, mycotic, parasitic and viral infections. The severe acute respiratory syndrome (SARS)-CoV2 (also referred to as COVID-19) coronavirus pandemic highlights the importance of understanding shared disease pathophysiology potentially informing therapeutic choices in individuals with Type 2 diabetes (T2D). Two coronavirus receptor proteins, Angiotensin Converting Enzyme 2 (ACE2) and Dipeptidyl Peptidase-4 (DPP4) are also established transducers of metabolic signals and pathways regulating inflammation, renal and cardiovascular physiology, and glucose homeostasis. Moreover, glucose-lowering agents such as the DPP4 inhibitors, widely used in subjects with T2D, are known to modify the biological activities of multiple immunomodulatory substrates. Here we review the basic and clinical science spanning the intersections of diabetes, coronavirus infections, ACE2, and DPP4 biology, highlighting clinical relevance and evolving areas of uncertainty underlying the pathophysiology and treatment of T2D in the context of coronavirus infection."],"journal":"Endocr Rev","authors":["Drucker, Daniel J"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294179","week":"202016|Apr 13 - Apr 19","doi":"10.1210/endrev/bnaa011","keywords":["angiotensin converting enzyme 2","diabetes","dipeptidyl peptidase-4","obesity","receptor","virus"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"e_drugs":["Glucose"],"_version_":1664636192676642816,"score":61.81732},{"pmid":32336007,"title":"DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19?","text":["DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19?","Dipeptidyl peptidase 4 (DPP4), also known as cluster of differentiation 26 (CD26), is a serine exopeptidase expressed ubiquitously in several tissues, including but not limited to lung, kidney, liver, gut, and immune cells. The question has been raised on whether DPP4 modulation or inhibition may prevent infection and/or progression of the COVID-19. A docked complex model of the SARS-CoV-2 spike glycoprotein and DPP4 has been proposed, showing a large interface between the proteins and proposing close similarity with other coronaviruses using DPP4 as functional receptor. In absence of experimental validation, these data should be interpreted with caution. Nevertheless, this observation may rise the question on whether DPP4 is directly involved in SARS-CoV-2 cell adhesion/virulence, and whether DPP4 inhibition might be a therapeutic strategy for preventing infection. Although a direct involvement of DPP4 in SARS-CoV-2 infection needs to be clarified, there is also evidence suggesting that DPP4i modulate inflammation and exert anti-fibrotic activity. These properties may be of potential use for halting progression to the hyperinflammatory state associated with severe COVID-19. Taken together these findings may suggest a potential role for DPP4 inhibition or modulation in one or more steps of COVID-19 immunopathogenesis. This article is protected by copyright. All rights reserved.","Diabetes Metab Res Rev","Strollo, Rocky","Pozzilli, Paolo","32336007"],"abstract":["Dipeptidyl peptidase 4 (DPP4), also known as cluster of differentiation 26 (CD26), is a serine exopeptidase expressed ubiquitously in several tissues, including but not limited to lung, kidney, liver, gut, and immune cells. The question has been raised on whether DPP4 modulation or inhibition may prevent infection and/or progression of the COVID-19. A docked complex model of the SARS-CoV-2 spike glycoprotein and DPP4 has been proposed, showing a large interface between the proteins and proposing close similarity with other coronaviruses using DPP4 as functional receptor. In absence of experimental validation, these data should be interpreted with caution. Nevertheless, this observation may rise the question on whether DPP4 is directly involved in SARS-CoV-2 cell adhesion/virulence, and whether DPP4 inhibition might be a therapeutic strategy for preventing infection. Although a direct involvement of DPP4 in SARS-CoV-2 infection needs to be clarified, there is also evidence suggesting that DPP4i modulate inflammation and exert anti-fibrotic activity. These properties may be of potential use for halting progression to the hyperinflammatory state associated with severe COVID-19. Taken together these findings may suggest a potential role for DPP4 inhibition or modulation in one or more steps of COVID-19 immunopathogenesis. This article is protected by copyright. All rights reserved."],"journal":"Diabetes Metab Res Rev","authors":["Strollo, Rocky","Pozzilli, Paolo"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32336007","week":"202018|Apr 27 - May 03","doi":"10.1002/dmrr.3330","keywords":["cd26","covid-19","dpp4 inhibitors","dipeptidyl peptidase 4","sars-cov-2","coronavirus"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1665172301969096704,"score":55.102398}]}